David Schneider, MD
Enriched profileProfessor of Medicine; Medical Director, Cardiovascular Medicine; Director, Cardiovascular Research Institute of Vermont · University of Vermont
David Schneider is Professor of Medicine; Medical Director, Cardiovascular Medicine; Director, Cardiovascular Research Institute of Vermont at University of Vermont. OpenAlex indexes 263 publications with 13,881 citations (h-index 53); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
David J. Schneider, MD, is Professor of Medicine at University of Vermont, Larner College of Medicine / UVM Medical Center (UVM Health Network). The public record shows 263 publications with 13,881 citations (h-index 53), centered on Coronary Artery Disease / ACS. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 2 companies, 4 NIH-funded awards (2000–2025).
- Most recent indexed publication: 2025 · Circulation. Cardiovascular interventions
- Top research focus: Coronary Artery Disease / ACS
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 3 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- "Care, Research and Education: Why Vermont Needs Academic Medicine"
op-ed opposing recommendations (from an Oliver Wyman consulting report) to cut clinician time spent on teaching and research …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uvmlarnermedblog.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa
Sponsor: Prolocor, Inc
- Cangrelor to Clopidogrel or Prasugrel Transition Study
Sponsor: The Medicines Company
- Cangrelor Prasugrel Transition Study
Sponsor: The Medicines Company
Industry payments
Updated 27 Aug 2026
2 companies reported payments to CMS in program years 2023–2025. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20251 payment
- Chiesi USA, Inc.Program year20232 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
93.8%Statin20.2%Rosuvastatin Calcium45%Atorvastatin Calcium41%Pravastatin Sodium8%Simvastatin6%Part D<11 patientsBeta blocker16.4%Carvedilol52%Metoprolol Succinate37%Atenolol6%Metoprolol Tartrate6%Part D<11 patientsBlood & clotting
6.2%Factor Xa inhibitor5.3%Eliquis100%Part D≥18 patientsP2Y12 inhibitor0.9%Clopidogrel100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 2000–2025 per NIH RePORTER. The latest:
- Computational Analyses of Family Auditory Communication: Linking Behavior, Vocalization, and Neural Dynamics
New York University
FY2026$854,818U01DA063581 - Platelet Expression of FcgammaRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
University of Southern California
FY2026$759,519R01NS123734
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Predictive Value of Platelet FcγRIIa in Patients Treated With PCI Compared With Medical Therapy Alone After Myocardial Infarction.
Circulation. Cardiovascular interventions
Article2025 - Platelet FcγRIIa Expression in Ischemic Stroke: A Marker of Increased Platelet Reactivity.
Stroke (Hoboken, N.J.)
Article2022
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Internal Medicine Residency and Chief Medical Residency
University of Colorado Health Sciences Center
- Fellowship in Cardiovascular Disease
Washington University, St. Louis
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vermontbiz.com ↗
- Chief of Cardiology
UVM Medical Center
Awards & honors
honors on the public recordSecondary affiliations
appointments beyond the home institution- Division of Cardiovascular Medicine
Department of Medicine, University of Vermont
Media & interviews
press, podcasts and appearances- "David Schneider, MD, Medical Director, Cardiovascular Services"
profile video, The UVM Medical Center (YouTube)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - "R1 Larner Spotlight: Cardiologist David Schneider, M.D., and a New Biomarker Test"
feature on Schneider's FcγRIIa/Prolocor pFCG platelet biomarker research
- "Biomarker test developed by UVMMC cardiologist offers insight to prevent recurrent heart attacks"
Vermont Business Magazine feature on Schneider's research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vermontbiz.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
David Krag, MD
University of Vermont
Robert Althoff, MD, PhD
University of Vermont
John Helzer, MD
University of Vermont
Neil Zakai, MD
University of Vermont